clinical trial · NCT07117669
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
N-Fold, LLC·phase2·recruiting·n = 68
Peanut AllergyENP-501Placebo
brief summary
This is a Phase 1/2 study to evaluate the safety and clinical activity of ENP-501 in non-peanut allergic (NPA) healthy participants and participants with an established peanut allergy (PA)
started
Dec 16, 2025
primary completion
Nov 1, 2028
completion
Nov 1, 2028
last updated
Apr 24, 2026
official title
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ENP-501 in Non-Peanut Allergic Participants and Participants With a Known Peanut Allergy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol